Describe the synthesis (what makes it and what catalyzes the reaction) and basic whereabouts of ACh.
PNS: all NMJ and parasympathetic nervous system
CNS: multiple cell bodies in cortical/subcortical regions and interneurons in striatum
Formed by Choline and Acetyl coenzyme A
Rate of synthesis controlled by
How is ACh packed and released?
Packed by VAChT vesicular ACh transporters
Pharmacology:
How is ACH degraded?
No direct reuptake.
Choline reuptaken by terminal via choline transporter.
Pharmacology
1. Hemicholinium-3 (HC-3) blocks choline transporters, reducing rate of ACh production BECAUSE its not allowing the choline to be reused! opposite to most other transport blockers :)
Describe AChE inhibitors.
Blocking AChE increases ACH buildup in synapse (more postsynaptic activation)
Example: Physostigmine: crosses blood brain barrier
- offset cognitive decline in Alzeimers for a short time (cause of loss of ACH neurons)
Irreversible inhibiton of AChE (with covalent bonds)
Describe the nicotinic ACH subtype
Ionotropic
Agonist: nicotine
Opens Na and Ca channels to enter the cell and depolarize membrane.
- fast response (excitatory) in CNS and PNS
5 subunits
Describe continuous activation of nicotinic receptors?
Describe some nicotinic pharmacology
Agonists:
Succinylcholine: muscle relaxant used in surgery
Antagonists:
Mecacylamine: blocks nicotinic receptors in CNS and autonomic ganglia (antidote for nicotinic poisoning in cerebral cortex) .
D-tubocurarine: blocks muscle nicotinic receptors
Some people are trying to develop more specific ones for cognitive enhancers or nicotinic addiction.
Describe the muscarinic receptor and subtypes
Metabotropic Agonist Muscarine (fly agaric mushrooms) 5 main subtypes (CNS or body) 2nd messengers or enhance K+ channel opening
Peripheral: cardiac and smooth muscle in many organs and insulin secreting pancreal cells
M2: cardiac ( slows heart rate when activated) and presynaptic autoreceptor in CNS
M3: smooth muscle (contraction -like digestive tract- when activated and other secretory responses -saliva and tears)
- drugs that act on muscarinic receptors have side effects like dry mouth cause blocking these receptors.
What is some pharmacology of muscarinic receptors.
Agonist
Pilocarpine: cholonergic poisioning. parasympathomimetic agent. activates parasympathetic neurons (M2 and M3)
- leads to SLUGDE response (salivation, lacrimation, urination, pooping, gastro issues and emesis)
-body produces stuff. not the same as nicotinic ones.
Antagonist
Atropine, Scopolamine
- inhibit parasympatheitc effects (look like sympatheitc effects)
- given to counteract too much ACH
- dilate pupils, reduce secretions that block things (like airways), counteract cholinergic poisoning.
- dries you up, and crosses the BBB
- CNS: sleepiness, euphoria, amnesia, fatigure, dreamless sleep because no rem
Describe ACh in the striatum.
Many central effects through M1 (also 3-5)
Striatum
-cholingergic interneurons.
- caudate, putamen, nucleus accumbens
- movement depends on balance between ACH and DA
I.E. parkinsons, DA is low, so ACH balance is high, which makes motor action selection hard. leads to random movements
- treated by reducing ACh early on before too many neurons are lost (low dose muscarinic agonist) instead of L-dopa
Describe ACH in the dorsolateral pons?
Tegmentum
Laterodorsal + Pedunculopontine nuclei
= project to thalamus, cerebellum and other cell groups (raphe, locus, VTA)
Within VTA (midbrain) ACH is exitatory on DA cells that create burst fire patterns.
Describe ACh in the basal forebrain.
Basal forebrain cholingergic system (BFCS) in lots of areas
that project to hippocampus, amygdala and cerebral cortex, and other limbic structures.
- emotional and cognitive regulation
How is attention measured? (assay for attention)
Signal Detection Task (measure of sustained attention)
- Signal trials and non-signal trials.
if you don’t get this go to slide 15 on ACH package.
What happens to attention if you manipulate ACH?
Systemic adminstration: we know impairs it
Microdialysis study: ACH in frontal cortex increases when performing attention task (but not when doing other things for controls)
ACH lesion study: selective basolateral forebrain lesion (192-IgG saporin) impaired perfomance on the hits but not correct rejections. Not random responding, they just weren’t paying attention so they missed the light sometimes.
optogenetics are starting now to see what happens if you stimulate or inhibit ACH (perfomr better and worse respectively)